XRCC1 Arg194Trp polymorphism, risk of nonmelanoma skin cancer and extramammary Paget’s disease in a Japanese population by Chiyomaru, Koji et al.
ORIGINAL PAPER
XRCC1 Arg194Trp polymorphism, risk of nonmelanoma skin
cancer and extramammary Paget’s disease in a Japanese
population
Koji Chiyomaru • Tohru Nagano • Chikako Nishigori
Received: 2 November 2011/Revised: 9 May 2012/Accepted: 11 May 2012/Published online: 26 May 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract The X-ray repair cross-complementing groups
1 gene plays an important role in base excision repair. At
least three common single nucleotide polymorphisms fre-
quently occur in this gene (Arg399Gln, Arg194Trp and
Arg280His). Recent studies reported that these polymor-
phisms were associated with not only risk of visceral
malignancy but also that of skin cancer such as basal cell
carcinoma and squamous cell carcinoma, whereas the
results of previous study vary among races. In this case–
control study, we investigated whether these single nucle-
otide polymorphisms were associated with the risk of skin
cancer in a Japanese population. The study population was
composed of 197 patients with skin cancer (27 actinic
keratoses, 47 basal cell carcinomas, 27 squamous cell
carcinomas, 29 Bowen’s diseases, 46 malignant melano-
mas and 21 extramammary Paget’s diseases) and 93
control subjects. We genotyped two single nucleotide
polymorphisms (Arg194Trp and Arg399Gln) using poly-
merase chain reaction-restriction fragments length poly-
morphism analysis. We found a signiﬁcantly increased risk
for basal cell carcinoma, squamous cell carcinoma and
extramammary Paget’s disease associated with Arg194Trp
[adjusted odds ratio (AOR) = 2.347, 3.587, 3.741, 95 %
conﬁdence interval (CI) 1.02–5.39, 1.19–10.8, 1.15–12.2,
respectively]. We also found a signiﬁcantly decreased risk
for basal cell carcinoma associated with Gln399Gln
(AOR = 0.259, 95 % CI 0.07–0.96). Our data suggest that
the Arg194Trp polymorphism could be associated with
nonmelanoma skin cancer and extramammary Paget’s
disease risk in a Japanese population.
Keywords Skin cancer   SNP   XRCC1
Introduction
‘‘Early detection, rapid cure’’ is most effective strategy for
cancer treatment. The outcome from educational cam-
paigns by oncologists has not been enough for reducing the
number of patients with advanced cancer. Furthermore, the
cost of medical expense is growing with each passing year.
Detection of high risk population for cancer seems to
become a practical way for educating people. For example,
detecting a DNA variation associated with cancer suscep-
tibility of each individual could become an effective
strategy for solving the problem.
Cancers are not single-gene diseases. Many oncogenes,
tumor suppressor genes and DNA repair genes are all likely
to be involved. DNA in most cells is regularly damaged by
endogenous and exogenous mutagens. Unrepaired damage
can result in apoptosis or may lead to unregulated cell
growth and cancer. Inheritance of genetic variants at one or
more loci results in reduced DNA repair capacity. DNA
repair enzymes have been reported to play an important
role in the carcinogenesis of several cancers. DNA repair
enzymes are involved in repairing damaged DNA and at
least four pathways operate on speciﬁc types of DNA
damage: the base excision repair (BER), nucleotide exci-
sion repair (NER), double strand break repair (DSBR) and
mismatch repair (MMR) pathways. Enzymes involved in
BER include XRCC1, those involved in NER include XPC,
XPD and ERCC1, those involved in DSBR include
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DOI 10.1007/s00403-012-1245-1BRCA1, BRCA2 and XRCC3, and those involved in MMR
include MLH1, MSH2, PMS2 and MSH6 [9].
From this standpoint, we focused on single nucleotide
polymorphisms(SNPs)oftheDNArepairgene,X-rayrepair
cross-complementing groups 1 (XRCC1) which was the ﬁrst
identiﬁed human gene involved in the repair of single strand
break (SSB) of DNA formed by exposure to ionizing radi-
ation and alkylating agents [20]. The SNPs may alter the
function and capacity of DNA repair. Although enzymatic
activity has not been revealed yet, XRCC1 interacts with
many proteins involved in base excision repair (BER) and
SSBrepair.IthasbeensupposedthatXRCC1playsaroleasa
scaffold protein for coordinating and facilitating the various
DNA repair pathways [11, 13]. The SNPs of XRCC1 has
been associated with a risk factor of cancers such as lung
cancer [3], breast cancer [15], prostate cancer [7, 19], and
also with skin cancers [6, 9, 17].
In the case of skin cancer, most people can see the lesion
by his or her own eyes. So the information about his/her
susceptibility to skin cancer enables him/her to realize
‘‘Early detection and rapid cure’’.
On the other hand, a contribution of SNPs to skin cancer
has ethnic and racial differences. In that way, further
insight into each society is important.
In the present study, we investigated the association
between polymorphisms of XRCC1 and skin cancer in a
Japanese population.
Materials and methods
Study population
One-hundred and ninety-seven patients (mean age ±
standard deviation (SD), 72.9 ± 12.2 years; age range
35–95 years) with skin cancer [27 actinic keratoses (AK),
47 basal cell carcinomas (BCC), 27 squamous cell carci-
nomas (SCC), 29 Bowen’s disease (BD), 46 malignant
melanomas (MM) and 21 extramammary Paget’s diseases
(EPD)] and 93 control subjects (mean age ± SD,
66.1 ± 13.7 years; age range 28–89) who visited the der-
matology clinic in Kobe University Hospital between April
2004 and November 2010 were enrolled in this study.
Clinical diagnosis was conﬁrmed by histopathological
analysis in all cases.
We subcategorized the patients according to the location
of cancer lesions whether on sun exposure site (head, neck
and hand) or not. The frequencies of BCC were: sun
exposure site, 89.4 % and not sun exposure site, 10.6 %.
Those of SCC were: sun exposure site, 51.9 % and not sun
exposure site, 48.1 %. Those of MM were: sun exposure
site, 17.4 % and not sun exposure site, 82.6 %.
The control group consists of 93 age- and sex-matched
non-affected unrelated Japanese individuals from the same
area in Japan with minor fungi, bacterial infections or
seborrheic keratosis. We excluded the patients with other
malignant disorders (Table 1).
We handled these patients as anonymous samples about
which nobody could know their personal information other
than their genotypes. Written informed consent was also
obtained from all participants. The Medical Ethics Com-
mittee of Kobe University approved this work that was
conducted in accordance with the Declaration of Helsinki
principles.
Genetics analysis
Genomic DNA was extracted from peripheral blood using
Qiagen FlexiGene DNA kit. The nucleotide changes were
determined by polymerase chain reaction-restriction frag-
ments length polymorphism (PCR-RFLP) analysis using
the isolated genomic DNA as a template. PCR for the
XRCC1 Arg194Trp (C[T) polymorphism was carried out
using primers 50 GCC CCG TCC CAG GTA 30 and 50 AGC
CCC AAG ACC CTT TCA CT 30. DNA was ampliﬁed for
35 cycles comprising denaturing at 94 C for 60 s,
annealing at 61 C for 60 s and extension at 72 C for 60 s.
The PCR products were detected after incubation with the
restriction endonuclease PvuII at 37 C for 2 h.
The forward and reverse primers for the XRCC1
Arg399Gln (G[A) polymorphism used were 50 CCC
CAA GTA CAG CCA GGT C 30 and 50 TGT CCC GCT
CCT CTC AGT AG 30, respectively. PCRs were run for 35
cycles: 94 C for 60 s, 62 C for 60 s, 72 C for 60 s, and
Table 1 Clinical characteristics and numbers among cases and controls
Characteristics Cases (with AK
diagnosis), No.
(%) (n = 27)
Cases (with
BCC diagnosis),
No. (%)
(n = 47)
Cases (with SCC
diagnosis), No.
(%) (n = 27)
Cases (with BD
diagnosis), No.
(%) (n = 29)
Cases (with MM
diagnosis), No.
(%) (n = 46)
Cases (with EPD
diagnosis), No.
(%) (n = 21)
Controls,
No. (%)
(n = 93)
Men 8 (29.6) 25 (53.2) 14 (51.9) 11 (37.9) 24 (52.2) 11 (52.4) 48 (51.6)
Women 19 (70.4) 22 (46.8) 13 (48.1) 18 (62.1) 22 (47.8) 10 (47.6) 45 (48.4)
AK actinic keratosis, BD bowen’s disease, BCC basal cell carcinoma, SCC squamous cell carcinoma, MM malignant melanoma, EPD extra-
mammary Paget’s disease
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123products were digested with the restriction endonuclease
MspIa t3 7  C for 2 h.
Statistical analysis
For statistical analysis, we used SPSS for Windows, ver-
sion 17.0 (SPSS Japan Inc.) to calculate the crude odds
ratio (OR), the adjusted odds ratio (AOR) and 95 % con-
ﬁdence interval (CI). All adjusted models included age and
sex.
Results
Polymorphisms of XRCC1 codons 194 and 399
and skin cancer risk
The XRCC1 gene polymorphisms Arg194Trp and Arg399
Gln were investigated. Their genotype distributions in skin
cancers and controls are shown in Table 2. We found a
signiﬁcantly increased risk for skin cancers associated with
Arg194Trp (AOR = 1.810, 95 % CI 1.03–3.18).
Polymorphisms of XRCC1 codons 194 and 399
and each category of skin cancer risk
We investigated the XRCC1 gene polymorphisms of codon
194 and 399 in the each skin cancer (Table 3). We found a
signiﬁcantly increased risk for BCC, SCC and EPD asso-
ciated with Arg194Trp (AOR = 2.347, 3.587, 3.741, 95 %
CI 1.02–5.39, 1.19–10.8, 1.15–12.2, respectively). We also
found a signiﬁcantly decreased risk for BCC associated
with Gln399Gln (AOR = 0.259, 95 % CI 0.07–0.96).
Polymorphisms of XRCC1 codons 194 and 399
and nonmelanoma skin cancer (NMSC) risk
Next we analyzed relationship between XRCC1 SNP and
NMSC (BCC and SCC) (Table 2). We found a signiﬁ-
cantly increased risk for NMSC associated with Arg194Trp
(AOR = 2.380, 95 % CI 1.15–4.95). We found a signiﬁ-
cantly decreased risk for NMSC associated with Gln399
Gln (AOR = 0.318, 95 % CI 0.11–0.92).
Discussion
In our present study, although our statistical analysis of
each skin cancer and controls had potential biases, a sig-
niﬁcantly increased risk for skin cancer was associated
with the SNP of XRCC1 Arg194Trp (AOR = 1.810, 95 %
CI 1.03–318) (Table 2). Two studies [6, 9] reported an
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123association of risk in skin cancer with XRCC1 Arg194Trp,
but the results were controversial. Han et al. reported the
increased risk of SCC with Arg194Trp, on the other hand,
Kang et al. reported the decreased risk of SCC with the
same SNP. These results indicate that the risk of skin
cancer in SNP in XRCC1 varies among races. In our
present study, the polymorphism of XRCC1 Arg194Trp has
been shown to be an important factor in susceptibility to
skin cancer among Japanese population.
Association of XRCC1 Arg194Trp could be not only
with MNSC but also with EPD (Tables 2, 3). Although the
number of each skin cancer has still been small, the
polymorphisms of XRCC1 Arg194Trp could be involved in
carcinogenesis of BCC and SCC. On the other hand, in the
case of AK and BD, XRCC1 Arg194Trp has no statistical
signiﬁcance, which indicates XRCC1 Arg194Trp would be
related to susceptibility to not in situ but advanced skin
cancer. In addition, actinic keratosis usually heralds SCC.
Many of SCC cases should also have AKs, thus, it could be
a useful indicator for the progression of the disease. Little
is known about the molecular mechanisms or genetic dis-
order of pathogenesis of EPD. It was reported that there
were high expressions of c-erb B2 and PIG7/LITAF in
EPD [12, 18], and Ki-67 and cycline D1 in invasive EPD
[1]. There is no report investigating the XRCC1 Arg194Trp
polymorphism in EPD. Since EPD occurs in sun-protected
areas, the true meaning of the SNPs in our patients needs to
be analyzed in a larger number of patients and in relation to
other genetic aberrations. As far as we know, our result is a
new indication for the relationship between polymorphism
of XRCC1 and EPD.
In the analysis of NMSC on the polymorphisms of
XRCC1, we found a signiﬁcantly increased risk with
Arg194Trp (AOR = 2.380, 95 % CI 1.15–4.95) and also
decreased risk with Gln399Gln (AOR = 0.318, 95 % CI
0.11–0.92). Previous reports showed that XRCC1 Gln399Gln
homozygote variant was associated with a signiﬁcantly
reduced risk of NMSC [17], which supported our results.
The inverse association of different loci (codon 194 and
399) of XRCC1 has been observed in previous reports
[6, 9]. The reason for this still remains unknown, several
factors relevant to this polymorphism, such as different
populations, different skin types [4] and differently dam-
aged levels of apoptotic mechanisms, might cause different
outcomes. Our data suggest that the Arg194Trp and
Arg399Gln polymorphisms may be differently associated
with NMSC in a Japanese population.
In the case of skin carcinogenesis, ultraviolet (UV) plays
an important role [5], especially in the induction of muta-
tions in both oncogenes and tumor suppressor genes [2, 8].
It has been reported that UV has been implicated in inhi-
bition of anti-tumor T-cell immune response through ele-
vated interleukin 10 (IL-10) and other cytokines level [21].
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123Recently, we have shown that IL-10 polymorphisms are
strongly correlated to sun-related skin cancers in a
Japanese population [16]. Therefore, we thought that under
the circumstances without UV effects, BER deﬁciency
could be more involved in carcinogenesis in the skin.
However, further analysis of our data indicated that poly-
morphism of XRCC1 codon 399 and 194 revealed much
more signiﬁcantly increased risk for BCC on sun-exposed
area associated with Arg194Trp and Arg194Trp ? Trp194
Trp (AOR = 3.304, 95 % CI 1.36–8.03 and AOR =
2.643, 95 % CI 1.19–5.89, respectively) (Table 4). Although
the case numbers are low in this study and thus, the statistical
powerislow,ourresultsindicateapossibilityofassociationof
the polymorphism of XRCC1 with UV-induced carcinogen-
esis. Actually, Moser et al. [14] indicated the association
of XRCC1 with not only BER but also with nucleotide
excision repair pathway which has a major role in repairing
UV-induced DNA damage.
The functional signiﬁcance of SNPs is still largely
unknown. Recent reports show that the SNPs of XRCC1
have been focused on not only in silico analysis but also on
in vitro and in vivo [10]. Further functional analyses of the
SNPs are needed.
Being different from visceral cancers, almost all skin
cancers are visible. Thus, early detection of skin anomaly
should be possible for not only medical doctors but also for
each individual. Nevertheless, there are still many patients
with advanced skin cancer. Thus, screening of skin cancer
risk for each individual enables them to know the impor-
tance of careful examination on their own skin in their
daily life, leading to reduction in both the number of
patients with advanced skin cancer and the cost of medical
expense.
Inconclusion,XRCC1genepolymorphisms,theArg194Trp
genotype increased the risk of NMSC and EPD in a
Japanese population. Consequently, this genotype could be
used as biomarkers for the estimation of skin cancer risk,
leading to education to the public, enabling the risk-indi-
viduals to obtain ‘‘Early detection and rapid cure’’.
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